Cargando…

Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma

Cancers avoid immune surveillance through an array of mechanisms, including perturbation of HLA class I antigen presentation. Merkel cell carcinoma (MCC) is an aggressive, HLA-I–low, neuroendocrine carcinoma of the skin often caused by the Merkel cell polyomavirus (MCPyV). Through the characterizati...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Patrick C., Klaeger, Susan, Le, Phuong M., Korthauer, Keegan, Cheng, Jingwei, Ananthapadmanabhan, Varsha, Frost, Thomas C., Stevens, Jonathan D., Wong, Alan Y.L., Iorgulescu, J. Bryan, Tarren, Anna Y., Chea, Vipheaviny A., Carulli, Isabel P., Lemvigh, Camilla K., Pedersen, Christina B., Gartin, Ashley K., Sarkizova, Siranush, Wright, Kyle T., Li, Letitia W., Nomburg, Jason, Li, Shuqiang, Huang, Teddy, Liu, Xiaoxi, Pomerance, Lucas, Doherty, Laura M., Apffel, Annie M., Wallace, Luke J., Rachimi, Suzanna, Felt, Kristen D., Wolff, Jacquelyn O., Witten, Elizabeth, Zhang, Wandi, Neuberg, Donna, Lane, William J., Zhang, Guanglan, Olsen, Lars R., Thakuria, Manisha, Rodig, Scott J., Clauser, Karl R., Starrett, Gabriel J., Doench, John G., Buhrlage, Sara J., Carr, Steven A., DeCaprio, James A., Wu, Catherine J., Keskin, Derin B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246387/
https://www.ncbi.nlm.nih.gov/pubmed/35775490
http://dx.doi.org/10.1172/JCI151666
_version_ 1784738959369175040
author Lee, Patrick C.
Klaeger, Susan
Le, Phuong M.
Korthauer, Keegan
Cheng, Jingwei
Ananthapadmanabhan, Varsha
Frost, Thomas C.
Stevens, Jonathan D.
Wong, Alan Y.L.
Iorgulescu, J. Bryan
Tarren, Anna Y.
Chea, Vipheaviny A.
Carulli, Isabel P.
Lemvigh, Camilla K.
Pedersen, Christina B.
Gartin, Ashley K.
Sarkizova, Siranush
Wright, Kyle T.
Li, Letitia W.
Nomburg, Jason
Li, Shuqiang
Huang, Teddy
Liu, Xiaoxi
Pomerance, Lucas
Doherty, Laura M.
Apffel, Annie M.
Wallace, Luke J.
Rachimi, Suzanna
Felt, Kristen D.
Wolff, Jacquelyn O.
Witten, Elizabeth
Zhang, Wandi
Neuberg, Donna
Lane, William J.
Zhang, Guanglan
Olsen, Lars R.
Thakuria, Manisha
Rodig, Scott J.
Clauser, Karl R.
Starrett, Gabriel J.
Doench, John G.
Buhrlage, Sara J.
Carr, Steven A.
DeCaprio, James A.
Wu, Catherine J.
Keskin, Derin B.
author_facet Lee, Patrick C.
Klaeger, Susan
Le, Phuong M.
Korthauer, Keegan
Cheng, Jingwei
Ananthapadmanabhan, Varsha
Frost, Thomas C.
Stevens, Jonathan D.
Wong, Alan Y.L.
Iorgulescu, J. Bryan
Tarren, Anna Y.
Chea, Vipheaviny A.
Carulli, Isabel P.
Lemvigh, Camilla K.
Pedersen, Christina B.
Gartin, Ashley K.
Sarkizova, Siranush
Wright, Kyle T.
Li, Letitia W.
Nomburg, Jason
Li, Shuqiang
Huang, Teddy
Liu, Xiaoxi
Pomerance, Lucas
Doherty, Laura M.
Apffel, Annie M.
Wallace, Luke J.
Rachimi, Suzanna
Felt, Kristen D.
Wolff, Jacquelyn O.
Witten, Elizabeth
Zhang, Wandi
Neuberg, Donna
Lane, William J.
Zhang, Guanglan
Olsen, Lars R.
Thakuria, Manisha
Rodig, Scott J.
Clauser, Karl R.
Starrett, Gabriel J.
Doench, John G.
Buhrlage, Sara J.
Carr, Steven A.
DeCaprio, James A.
Wu, Catherine J.
Keskin, Derin B.
author_sort Lee, Patrick C.
collection PubMed
description Cancers avoid immune surveillance through an array of mechanisms, including perturbation of HLA class I antigen presentation. Merkel cell carcinoma (MCC) is an aggressive, HLA-I–low, neuroendocrine carcinoma of the skin often caused by the Merkel cell polyomavirus (MCPyV). Through the characterization of 11 newly generated MCC patient-derived cell lines, we identified transcriptional suppression of several class I antigen presentation genes. To systematically identify regulators of HLA-I loss in MCC, we performed parallel, genome-scale, gain- and loss-of-function screens in a patient-derived MCPyV-positive cell line and identified MYCL and the non-canonical Polycomb repressive complex 1.1 (PRC1.1) as HLA-I repressors. We observed physical interaction of MYCL with the MCPyV small T viral antigen, supporting a mechanism of virally mediated HLA-I suppression. We further identify the PRC1.1 component USP7 as a pharmacologic target to restore HLA-I expression in MCC.
format Online
Article
Text
id pubmed-9246387
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-92463872022-07-02 Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma Lee, Patrick C. Klaeger, Susan Le, Phuong M. Korthauer, Keegan Cheng, Jingwei Ananthapadmanabhan, Varsha Frost, Thomas C. Stevens, Jonathan D. Wong, Alan Y.L. Iorgulescu, J. Bryan Tarren, Anna Y. Chea, Vipheaviny A. Carulli, Isabel P. Lemvigh, Camilla K. Pedersen, Christina B. Gartin, Ashley K. Sarkizova, Siranush Wright, Kyle T. Li, Letitia W. Nomburg, Jason Li, Shuqiang Huang, Teddy Liu, Xiaoxi Pomerance, Lucas Doherty, Laura M. Apffel, Annie M. Wallace, Luke J. Rachimi, Suzanna Felt, Kristen D. Wolff, Jacquelyn O. Witten, Elizabeth Zhang, Wandi Neuberg, Donna Lane, William J. Zhang, Guanglan Olsen, Lars R. Thakuria, Manisha Rodig, Scott J. Clauser, Karl R. Starrett, Gabriel J. Doench, John G. Buhrlage, Sara J. Carr, Steven A. DeCaprio, James A. Wu, Catherine J. Keskin, Derin B. J Clin Invest Research Article Cancers avoid immune surveillance through an array of mechanisms, including perturbation of HLA class I antigen presentation. Merkel cell carcinoma (MCC) is an aggressive, HLA-I–low, neuroendocrine carcinoma of the skin often caused by the Merkel cell polyomavirus (MCPyV). Through the characterization of 11 newly generated MCC patient-derived cell lines, we identified transcriptional suppression of several class I antigen presentation genes. To systematically identify regulators of HLA-I loss in MCC, we performed parallel, genome-scale, gain- and loss-of-function screens in a patient-derived MCPyV-positive cell line and identified MYCL and the non-canonical Polycomb repressive complex 1.1 (PRC1.1) as HLA-I repressors. We observed physical interaction of MYCL with the MCPyV small T viral antigen, supporting a mechanism of virally mediated HLA-I suppression. We further identify the PRC1.1 component USP7 as a pharmacologic target to restore HLA-I expression in MCC. American Society for Clinical Investigation 2022-07-01 2022-07-01 /pmc/articles/PMC9246387/ /pubmed/35775490 http://dx.doi.org/10.1172/JCI151666 Text en © 2022 Lee et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Lee, Patrick C.
Klaeger, Susan
Le, Phuong M.
Korthauer, Keegan
Cheng, Jingwei
Ananthapadmanabhan, Varsha
Frost, Thomas C.
Stevens, Jonathan D.
Wong, Alan Y.L.
Iorgulescu, J. Bryan
Tarren, Anna Y.
Chea, Vipheaviny A.
Carulli, Isabel P.
Lemvigh, Camilla K.
Pedersen, Christina B.
Gartin, Ashley K.
Sarkizova, Siranush
Wright, Kyle T.
Li, Letitia W.
Nomburg, Jason
Li, Shuqiang
Huang, Teddy
Liu, Xiaoxi
Pomerance, Lucas
Doherty, Laura M.
Apffel, Annie M.
Wallace, Luke J.
Rachimi, Suzanna
Felt, Kristen D.
Wolff, Jacquelyn O.
Witten, Elizabeth
Zhang, Wandi
Neuberg, Donna
Lane, William J.
Zhang, Guanglan
Olsen, Lars R.
Thakuria, Manisha
Rodig, Scott J.
Clauser, Karl R.
Starrett, Gabriel J.
Doench, John G.
Buhrlage, Sara J.
Carr, Steven A.
DeCaprio, James A.
Wu, Catherine J.
Keskin, Derin B.
Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma
title Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma
title_full Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma
title_fullStr Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma
title_full_unstemmed Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma
title_short Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma
title_sort reversal of viral and epigenetic hla class i repression in merkel cell carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246387/
https://www.ncbi.nlm.nih.gov/pubmed/35775490
http://dx.doi.org/10.1172/JCI151666
work_keys_str_mv AT leepatrickc reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT klaegersusan reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT lephuongm reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT korthauerkeegan reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT chengjingwei reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT ananthapadmanabhanvarsha reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT frostthomasc reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT stevensjonathand reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT wongalanyl reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT iorgulescujbryan reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT tarrenannay reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT cheavipheavinya reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT carulliisabelp reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT lemvighcamillak reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT pedersenchristinab reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT gartinashleyk reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT sarkizovasiranush reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT wrightkylet reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT liletitiaw reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT nomburgjason reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT lishuqiang reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT huangteddy reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT liuxiaoxi reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT pomerancelucas reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT dohertylauram reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT apffelanniem reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT wallacelukej reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT rachimisuzanna reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT feltkristend reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT wolffjacquelyno reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT wittenelizabeth reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT zhangwandi reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT neubergdonna reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT lanewilliamj reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT zhangguanglan reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT olsenlarsr reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT thakuriamanisha reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT rodigscottj reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT clauserkarlr reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT starrettgabrielj reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT doenchjohng reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT buhrlagesaraj reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT carrstevena reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT decapriojamesa reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT wucatherinej reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma
AT keskinderinb reversalofviralandepigenetichlaclassirepressioninmerkelcellcarcinoma